All eCQMs associated with: Management of Chronic Conditions
| Year | Type | CMS eCQM ID | Measure Name |
|---|---|---|---|
| 2022 | EP/EC | CMS122v10 | Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) |
| 2020 | EP/EC | CMS122v8 | Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) |
| 2021 | EP/EC | CMS122v9 | Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) |
| 2022 | EP/EC | CMS131v10 | Diabetes: Eye Exam |
| 2020 | EP/EC | CMS131v8 | Diabetes: Eye Exam |
| 2021 | EP/EC | CMS131v9 | Diabetes: Eye Exam |
| 2022 | EP/EC | CMS133v10 | Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
| 2020 | EP/EC | CMS133v8 | Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
| 2021 | EP/EC | CMS133v9 | Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
| 2022 | EP/EC | CMS134v10 | Diabetes: Medical Attention for Nephropathy |
| 2020 | EP/EC | CMS134v8 | Diabetes: Medical Attention for Nephropathy |
| 2021 | EP/EC | CMS134v9 | Diabetes: Medical Attention for Nephropathy |
| 2022 | EP/EC | CMS135v10 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| 2020 | EP/EC | CMS135v8 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| 2021 | EP/EC | CMS135v9 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| 2022 | EP/EC | CMS143v10 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
| 2020 | EP/EC | CMS143v8 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
| 2021 | EP/EC | CMS143v9 | Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
| 2022 | EP/EC | CMS144v10 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| 2020 | EP/EC | CMS144v8 | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |